Human minor histocompatibility antigens: New concepts for marrow transplantation and adoptive immunotherapy

Immunological Reviews

Volumn 157, Issue , 1997, Pages 125-140

  Goulmy, Els ^a  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

MINOR HISTOCOMPATIBILITY ANTIGEN;

ADOPTIVE IMMUNOTHERAPY; BONE MARROW TRANSPLANTATION; GRAFT VERSUS HOST REACTION; HUMAN; LEUKEMIA; PRIORITY JOURNAL; REVIEW;

ANIMALS; BONE MARROW TRANSPLANTATION; GRAFT VS HOST DISEASE; HUMANS; IMMUNOTHERAPY, ADOPTIVE; MINOR HISTOCOMPATIBILITY ANTIGENS;

EID: 0030754892     PISSN: 01052896     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1600-065X.1997.tb00978.x     Document Type: Review

References (167)

1. Snell GD. Methods for the study of histocompatibility genes. J Genet 1948;49:87-103.
2. Counce S, Smith P, Barter R, Snell GD. Strong and weak histocompatibility fine differences in mice and their role in the rejection of homografts of tumors and skin. Ann Surg 1956;144:1988-2204.
3. Graff RJ, Bailey DW. The non H-2 histocompatibility loci and their antigens. Transplant Rev 1973;15:26-49.
4. Schultz JS, Beals TF, Petraïtis FP. Tissue graft rejection in mice. I. Contributions of H-2 and non H-2 genetic barriers. Immunogenetics 1976;3:85-96.
5. Zinkernagel RM, Doherty PC. Restriction of in vitro T cell mediated cytotoxicity in lymphocytic choriomeningitis with a syngeneic or semiallogeneic system. Nature 1974;248:701-702.
6. Bevan MH. The major histocompatibility complex determines susceptibility to cytotoxic T cells directed against minor histocompatibility antigens. J Exp Med 1975;142:1349-1364.
7. Gordon RD, Simpson E, Samuelson LE. In vitro cell mediated immune response to the male specific (H-Y) antigen in mice. J Exp Med 1975;142:1108-1120.
8. Goulmy E, Termijtelen A, Bradley BA, Van Rood JJ. Alloimmunity to human H-Y. Lancet 1976;ii:1206.
9. Goulmy E, Termijtelen A, Bradley BA, Van Rood JJ. Y-antigen killing by T cells of women is restricted by HLA. Nature 1977;266:544-545.
10. Bjorkman PJ, Saper MA, Samraoui B, Bennett WS, Strominger JL, Wiley DC. The foreign antigen binding site and T cell recognition regions of class I histocompatibility antigens. Nature 1987;329:512-518.
11. Townsend ARM, Rotbard J, Gotch FM, Bahadur G, Waraith D, McMichael AJ. The epitopes of influenza nucleoprotein recognized by cytotoxic T lymphocytes can be defined with short synthetic peptides. Cell 1986;44:959-968.
12. Townsend A. Recognition of influenza virus proteins by CTL. Immunol Res 1987;6:80-100.
13. Rötzschke O, Falk K, Wallny H-J, Faath S, Rammensee HG. Characterization of naturally occurring minor histocompatibility peptides including H-4 and H-Y. Science 1989;249:283-287.
14. Falk K, Rötzschke O, Rammensee HG. Cellular peptide composition governed by major histocompatibility complex class I molecules. Nature 1990;348:248-251.
15. Fisher Lindahl K, Hermel E, Loveland BE and Wang CR. Maternally transmitted antigen of mice: a model transplantation antigen. Annu Rev Immunol 1991;9:351-372.
16. Den Haan JMM, et al. Identification of graft-versus-host disease associated human minor histocompatibility antigen. Science 1995;268:1478-1480.
17. Eichwald EJ, Slimser CR. Transplant Bull 1955;2:148-149.
18. Billingham RE, Silvers WK. Studies on tolerance of the Y chromosome antigen in mice. J Immunol 1960;85:14-26.
19. + T cells with genuine class I restriction. Eur J Immunol 1992;22:875-878.
20. Voogt PJ, et al. Rejection of bone-marrow graft by recipient derived cytotoxic T lymphocytes against minor histocompatibility antigens. Lancet 1990;335:131-134.
21. Voogt PJ, et al. Minor histocompatibility antigen H-Y is expressed in human haematopoietic progenitor cells. J Clin Invest 1988;82:906-912.
22. Singal DP, Wadia YJ, Naipaul N. In vitro cell-mediated cytotoxicity to the male specific H-Y antigen in man. Hum Immunol 1981;2:45-53.
23. Pfeffer PF, Thorsby E. HLA restricted cytotoxicity against male specific (H-Y) antigen after acute rejection of an HLA identical sibling kidney: clonal distribution of the cytotoxic cells. Transplantation 1982;33:52-56.
24. + cytotoxic T lymphocyte clones from a patient with severe graft-versus-host disease after allogeneic bone marrow transplantation: implications for graft-versus-leukemia reactivity. Blood 1995;86:2821-2828.
25. Horai S, Van der Poel JJ, Goulmy E. Differentia] recognition of the serologically defined HLA-A2 antigen by allogeneic cytotoxic T cells. I. Population studies. Immunogenetics 1982;16:135-142.
26. Van der Poel JJ, Pool J, Goulmy E, Giphart MJ, Van Rood JJ. Recognition of distinct epitopes on the HLA-A2 antigen by cytotoxic T lymphocytes. Hum Immunol 1986;16:247-258.
27. Goulmy E, Van der Poel JJ, Giphart M, Van Rood JJ. Analysis of the functional epitopes on different HLA-A2 molecules. Immunogenetics 1984;20:13-21.
28. Ezquerra A, Doménech N, Van der Poel JJ, Strominger JL, Vega MA, Lopéz de Castro JA. Molecular analysis of an HLA-A2 functional variant Cla defined by cytolytic T lymphocytes. J Immunol 1986;136:1642-1649.
29. Goulmy E, Van Leeuwen A, Blokland E, Sachs ES, Geraedts JPM. The recognition of abnormal sex chromosome constitution by HLA restricted anti-H-Y cytotoxic T cells and antibody. Immunogenetics 1983;17:523-531.
30. Simpson E, Chandler P, Goulmy E, Disteche CM, Ferguson-Smith MA, Page DC. Separation of the genetic loci for the H-Y antigen and for testis determination on human Y chromosome. Nature 1987;326:876-878.
31. Simpson E, Chandler P, Goulmy E, Ma K, Bargreave TB, Chandley AC. Loss of the 'azoospermia factor' (AZF) on Yq in man is not associated with loss of HYA. Hum Mol Genet 1993;2:469-471.
32. Cantrell MA, et al. Deletion mapping of H-Y antigen to the long arm of the human Y chromosome. Genomics 1992;13:1255-1260.
33. O'Reilly AJ, Affara MA, Simpson E, Chandler P, Goulmy E, Ferguson-Smith MA. A molecular deletion map of the Y chromosome long arm defining X and autosomal homologous regions and the localisation of the HYA locus to the proximal region of the Yq euchromatin. Hum Mol Genet 1992;1:379-385.
34. Hunt DF, et al. Characterization of peptides bound to dass I MHC molecule HLA-A2.1 by mass spectrometry. Science 1992;255:1261-1263.
35. Wang W, et al. Human H-Y: a male-specific histocompatibility antigen derived from the SMCY protein. Science 1995;269:1588-1590.
36. a region of the mouse Y chromosome and reveals complexity of the Hya locus. Genomics 1994;24:159-168.
37. Scott DN, et al. Identification of a mouse male specific transplantation antigen H-Y. Nature 1995;376:695-698.
38. Meadows L, et al. The H-Y antigen presented by HLA-A*0201 contains a posttranslationally modified cysteine residue: a common peptide modification that significantly affects T cell recognition. Immunity 1997;6:273-281.
39. Simmons WA, et al. Novel HY peptide antigens by HLA-B27. J Immunol (In press).
40. b epitope is encoded by a novel mouse Y chromosome gene. Nature Genetics 1996;14:474-478.
41. Agulnik AI, Mitchell MJ, Lerner JC, Woods DR, Bishop CE: A mouse Y chromosome gene encoded by a region essential for spermatogenesis and expression of male specific minor histocompatibility antigens. Hum Mol Genet 1994;3:873-878.
42. Den Haan JJM, et al. Conservation of minor histocompatibility antigens between human and non-human primates. Eur J Immunol 1996;26:2680-2685.
43. Kent-First MG, Maffitt M, Muallem A, Brisco P, Shultz J, Ekenberg S. Gene sequence and evolutionary conservation of human SMCY. Nature Genetics 1996;14:128-129.
44. De Bueger M, Bakker A, Van Rood JJ, Van der Woude F, Goulmy E. Tissue distribution of human minor histocompatibility antigens ubiquitous versus restricted tissue distribution indicates heterogeneity among human cytotoxic T lymphocyte-defined non-MHC antigens. J Immunol 1992;14:1788-1794.
45. Report from the International Bone Marrow Transplant Registry. Bone Marrow Transplant 1989;4:221-228.
46. Goulmy E, et al. Mismatches of minor histocompatibility antigen between HLA-identical donor and recipients and the development of graft-versus-host disease after bone marrow transplantation. N Engl J Med 1996;334:281-285.
47. Ramsay NKC, et al. A randomized study of the prevention of acute graft-versus-host disease. N Engl J Med 1982;306:392-397.
48. Ellison MD, Norman DJ, Breen TJ, Edwards EB, Davies DB, Daily OP. No effect of H-Y minor histocompatibility antigen in zero-mismatched living-donor renal transplants. Brief communications. Transplantation 1994;58:518-530.
49. Boak JL, Wilson RE. Modification of the graft-versus-host syndrome by anti-lymphocyte serum treatment of the donor. Clin Exp Immunol 1968;3:795-800.
50. Korngold R, Sprent J. Lethal graft-versus host-disease after bone marrow transplantation across minor histocompatibility barriers in mice: prevention by removing mature T cells from marrow. J Exp Med 1978;148:1687-1698.
51. Hamilton BL. L3T4 positive T cells participate in the induction of graft vs host disease in response to minor histocompatibility antigens. J Immunol 1987;139:2511-2515.
52. Berger M, Wettstein PJ, Korngold R. T cell subsets involved in lethal graft-versus-host disease directed to immunodominant minor histocompatibility antigens. Transplantation 1994;57:1095-1102.
53. Parkman R. Clonal analysis of murine graft-vs-host disease. I. Phenotypic and functional analysis of T lymphocyte clones. J Immunol 1986;136:3543-3548.
54. Korngold R, Sprent R. Features of T cells causing H-2 restricted lethal graft-versus-host disease across minor histocompatibility barriers. J Exp Med 1982;155:872-883.
55. Kindred B. Preliminary characterization of the cells cause a H-2 restricted GvH reaction. Immunogenetics 1984;19:243-248.
56. + T cells to cause lethal graft-versus-host disease across minor histocompatibility barriers in mice. J Exp Med 1987;165:1552-1564.
57. Cobbold SPO, Martin G, Waldmann H. Monoclonal antibodies for prevention of graft-versus-host disease and marrow graft rejection: the depletion of T cell subsets in vitro and in vivo. Transplantation 1986;42:239-247.
58. Wettstein PJ, Korngold R. T cell subsets required for in vivo and in vitro responses to single and multipe minor histocompatibility antigens. Transplantation 1992;54:296-307.
59. + cells can initiate human graft-versus-host disease. Transplant Proc 1987;19:2879-2881.
60. Champlin R, et al. Retention of graft versus host leukemia using selective depletion of CD8 positive T lymphocytes for prevention of graft versus host disease following bone marrow transplantation for chronic myelogenous leukemia. Transplant Proc 1991;23:1695-1696.
61. Maraninchi D, et al. Selective depletion of marrow T cytotoxic lymphocytes (CD8) in the prevention of graft-versus-host disease after allogeneic bone marrow transplantation. Transpl Int 1988;1:91-94.
62. Van Els C, Bakker A, Zwinderman AH, Zwaan FE, Van Rood JJ, Goulmy E. Effector mechanisms in GVHD in response to minor histocompatibility antigens. I. Absence of correlation with CTLs. Transplantation 1990;50:62-66.
63. De Bueger M, Bakker A, Bontkes H, Van Rood JJ, Goulmy E. High frequencies of cytotoxic T cell precursors against minor histocompatibility antigens after HLA-identical BMT: absence of correlation with GVHD. Bone Marrow Transplant 1993;11:363-368.
64. Hamilton BL. Absence of correlation between cytolytic T lymphocytes and lethal murine graft-versus-host disease in response to minor histocompatibility antigens. Transplantation 1984;38:357-360.
65. Fontaine P, Langlais J, Perrault C. Evaluation of in vitro CTL assays as a predictive test for the occurrence of graft vs host disease. Immunogenetics 1991;34:222-226.
66. Goulmy E, Gratama JW, Blokland E, Zwaan FE, Van Rood JJ. Recognition of an -as yet unknown- minor transplantation antigen by posttransplant lymphocytes from an AML patient. Exp Hematol 1982;10:127-129.
67. Tsoi M-S, Storb R, Dobbs S, Medill I, Thomas ED. Cell mediated immunity to non-HLA antigens of the host by donor lymphocytes in patients with chronic graft-vs-host disease. J Immunol 1980;125:2258-2262.
68. Tsoi M-S, Storb R, Santos E, Thomas ED. Anti-host cytotoxic cells in patients with acute graft-versus-host disease after HLA identical marrow grafting. Transplant Proc 1983;15:1484-1486.
69. Irlé C, Beatty PG, Mickelson E, Thomas ED, Hansen JA. Alloreactive T cell responses between HLA identical siblings. Transplantation 1985;40:329-333.
70. Irschick E, et al. Studies on the mechanism of tolerance or graft-versus-host disease in allogeneic bone marrow recipients at the level of cytotoxic T cell precursor frequencies. Blood 1992;79:1622-1628.
71. Niederwieser D, et al. Correlation of minor histocompatibility antigen specific cytotoxic T lymphocytes with graft-versus-host disease status and analyses of tissue distribution of their target antigens. Blood 1993;81:2200-2208.
72. Mirijt EAF, et al. Multiple minor histocompatibility antigen disparities between a recipient and four HLA identical potential sibling donors for bone marrow transplantation. Hum Immunol 1993;37:221-228.
73. Kasten-Sportès C, Masset M, Varrin F, Devergie A, Gluckman E. Phenotype and function of T lymphocytes infiltrating the skin during graft-versus-host disease following allogeneic bone marrow transplantation. Transplantation 1989;47:621-624.
74. Reinsmoen NL, Kersey JH, Bach FH. Detection of HLA restricted anti minor histocompatibility antigen(s) reactive cells from skin GVHD lesions. Hum Immunol 1984;1:249-257.
75. Irlé C, Chapuis B, Jeannet M, Kaestli M, Montandon N, Speck B. Detection of anti-non-MHC-directed T cell reactivity following in vivo priming after HLA identical marrow transplantation and following in vitro priming in limiting dilution cultures. Transplant Proc 1987;19:2674-2677.
76. Van Els CACM, Bakker A, Zwinderman AH, Zwaan FE, Van Rood JJ, Goulmy E. Effector mechanisms in GVHD in response to minor histocompatibility antigens. II. Evidence for a possible involement of proliferative T cells. Transplantation 1990;50:67-71.
77. Van Els C, Zandvoort E, Jacobs N, Bakker A, Van Rood JJ, Goulmy E. Graft-versus-host disease associated T helper cell responses specific for minor histocompatibility antigens are mainly restricted by HLA-DR molecules. Bone Marrow Transplant 1990;5:365-372.
78. Nierle T, Bunjes D, Arnold R, Heimpel H, Theobald M. Quantitative assessment of posttransplant host specific interleukin-2 secreting T helper cell precursors in patients with and without acute graft-versus-host disease after allogeneic HLA identical sibling bone marrow transplantation. Blood 1993;81:841-848.
79. Theobald M, Nierle T, Bunjes D, Arnold R, Heimpel H. Host specific interleukin-2 secreting donor T cell precursors as predictors of acute graft-versus-host disease in bone marrow transplantation between HLA identical siblings. N Engl J Med 1992;327:1613-1617.
80. Schwarer AP, Jiang JP, Barrett JM, Batchelor JR, Goldman JM, Lechler RI. Helper T lymphocyte precursor (HTLp) frequency predicts the occurrence and severity of acute GVHD and survival after allogeneic BMT in both recipients of genotypically HLA-identical sibling (SIB) and phenotypically HLA-matched unrelated donor (MUD) marrow. Lancet 1993;341:203-205.
81. +T cell subsets. Blood 1993;82:298-306.
82. Goulmy E, Gratama JW, Blokland E, Zwaan FE, Van Rood JJ. A minor transplantation antigen detected by MHC restricted cytotoxic T lymphocytes during graft-versus-host-disease. Nature 1983;302:159-161.
83. Goulmy E. Lifting a tip of the veil of human minor histocompatibility antigens. In: Zander AR, Ostertag W, Afanasiev BV, Grosveld F, eds. Gene Technology. NATO ASI Series (94). Berlin: Springer Verlag; 1996.p.353-359.
84. Neisig A, Wubbolts R, Zang X, Melief C, Neefjes J. Allele-specific differences in the interaction of MHC class I molecules with transporters associated with antigen processing. J Immunol 1996;156:3196-3206.
85. 84a. Momburg F, et al. Proteasome subunits encoded by the major histocompatibility complex are not essential for antigen presentation. Nature 1992;360:174-177.
86. 84b. Goulmy E. Minor histocompatibility antigen matching: actual fact or wishful thinking? Bone Marrow Transplant 1995;15:59-62.
87. Van Els C, D'Amaro J, Pool J, Bauer A, Van den Elsen PJ, Van Rood JJ, Goulmy E. Immunogenetics of human minor histocompatibility antigens: their polymorphism and immunodominance. Immunogenetics 1992;35:161-165.
88. Schreuder GMTH, et al. Genetic analysis of human minor histocompatibility antigens demonstrates Mendelian segregation independent from HLA. Immunogenetics 1993;38:98-105.
89. Goulmy E, Hamilton JD, Bradley BA. Anti-self HLA may be clonally expressed. J Exp Med 1979;149:545-550.
90. Goulmy E, Pool J, Van den Elsen PJ. Interindividual conservation of T cell receptor β chain variable regions by minor histocompatibility antigen specific HLA-A*0201 restricted cytotoxic T cell clones. Blood 1995;85:2478-2481.
91. Goulmy E. Human minor histocompatibility antigens. Curr Opin Immunol 1996;8:75-81.
92. Zier KS, Elkins WL, Pierson GR, Leo MM. The use of cytotoxic T cell lines to detect the segregation of a human minor alloantigen within families. Hum Immunol 1983;6:117-129.
93. Irlé C, Beatty PG, Mickelson E, Donnall TE, Hansen JA. Alloreactive T cell responses between HLA identical siblings. Detection of anti-tumor histocompatibility T cell clones induced in vivo. Transplantation 1995;40:329-333.
94. Beck Y, et al. Isolation of human minor histocompatibility peptides from cultured kidney cells. Transplant Proc 1993;25:162-166.
95. Yamamoto J, Kariyone A, Akiyama N, Kano K, Takiguchi M. Presentation of human minor histocompatibility antigens by HLA-B35 and HLA-B38 molecules. Proc Natl Acad Sci USA 1990;87:2583-2587.
96. Vinci G, Masset M, Semana G, Vernant J-P. A human minor histocompatibility antigen which appears to segregate with the major histocompatibility complex. Transplantation 1994;58:361-367.
97. Gubarev MI, et al. Localization to chromosome 22 of a gene encoding a human minor histocompatibility antigen. J Immunol 1996;157:5448-5454.
98. Dolstra H, et al. Recognition of a B cell leukemia-associated minor histocompatibility antigen by CTL. J Immunol 1997;158:560-565.
99. Mickelson EM, Beatty PG, Storb R, Hansen JA. Immune responses in an untransfected patient with aplastic anemia: analysis of cytolytic and proliferative T cell clones. Hum Immunol 194;10:189-201.
100. Tilkin AF, Bagot M, Kayibanda M, Vernant JP, Levy JP. Human autoreactive T cell line specific for minor histocompatibility antigen(s) isolated from a bone marrow-grafted patient. Transplantation 1986;137:3772-3776.
101. Nishimura M, Akaza T, Mitomi Y, Nieda M, Minami M, Juji T. Establishment of human minor histocompatibility antigen-specific cytotoxic T cell clones resticted by HLA-DR9. Transplantation 1993;44:181-186.
102. Beck Y, et al. Expression of human minor histocompatibility antigen on cultured kidney cells. Eur J Immunol 1993;23:467-472.
103. Colombo MP, Jaenisch R, Wettstein PJ. Endogenous retroviruses lead to the expression of a histocompatibility antigen detectable by skin graft rejection. Proc Natl Acad Sci USA 1987;84:193-198.
104. Wettstein PJ, Jewett L, Faas S, Brinster RL, Knowles BB. SV40-antigen is a histocompatibility antigen of SV40-transgenic mice. Immunogenetics 1988;27:436-441.
105. Boon T, Van Pel A. T cell recognized antigenic peptides derived from the cellular genome are not protein degradation products but can be generated directly by transcription and translation of short subgenic regions, a hypothesis. Immunogenetics 1989;29:75-79.
106. Rammensee H-G, Robinson PJ, Crisanti A, Bevan MJ. Restricted recognition of β2m by cytotoxic T lymphocytes. Nature 1986;319:502-504.
107. Speiser DE, et al. Nuclear myxovirus-resistance protein Mx is a minor histocompatibility antigen. Proc Natl Acad Sci USA 1990;87:2021-2025.
108. Loveland BE, Wang CR, Yonekawa H, Hermel E, Fischer Lindahl K. Maternally transmitted histocompatibility antigen of mice: a hydrophobic peptide of a mitochondrially encoded protein. Cell 1990;60:971-980.
109. Elkins WL, Pierson GR, Storb R. Study of a human minor alloantigen in relation to clinical graft-versus-host disease. Bone Marrow Transpl 1987;1:397-403.
110. Behar E, et al. Polymorphism of adhesion molecule CD31 and its role in acute graft-versus-host disease. N Engl J Med 1996;334:286-291.
111. Nichols C, et al. Polymorphism of adhesion molecule CD31 is not a significant risk factor for graft-versus-host disease. Blood 1996;88:4429-4434.
112. Graff RJ, Hildemann WH, Snell GD. Histocompatibility genes of mice. VI. Allografts in mice congenic at various non-H-2 histocompatibility loci. Transplantation 1966;4:425-437.
113. Johnson LJ, Bailey DW, Mobraaten LE. Anigenic competition between minor (non-H-2) histocompatibility antigens. Immunogenetics 1981;13:451-455.
114. Wettstein PJ, Bailey DW. Immunodominance in the immune response to 'multiple' histocompatibility antigens. Immunogenetics 1982;16:47-82.
115. Wettstein PJ. Immunodominance in the T cell response to multiple non-H-2 histocompatibility antigens. II. Observation of a hierarchy among dominant antigens. Immunogenetics 1986;24:24-31.
116. Wettstein PJ, Colombo MP. Immunodominance in the T cell response to multiple non-H-2 histocompatibility antigens. IV. Partial tissue distribution and mapping of immunodominant antigens. J Immunol 1987;139:2166-2171.
117. Korngold R, Wettstein PJ. Immunodominance in the graft-vs-host disease T cell response to minor histocompatibility antigens. J Immunol 1990;145:4079-4088.
118. Vagliani M, Melani C, Parmiani G, D'Eustachio P, Wettstein PJ, Colombo MP. Immunodominance in the T cell response to multiple non-H-2 histocompatibility antigens. V. Chromosomal mapping of the immunodominant cytotoxic T cell target-1 (CTT-1). Immunogenetics 1993;38:157-160.
119. Yin L, Poirier G, Neth O, Hsuan JJ, Totty NF, Stauss HJ. Few peptides dominate cytotoxic T lymphocyte responses to single and multiple minor histocompatibility antigens. Int Immunol 1993;5:1003-1009.
120. Franksson L, Petersson M, Kiessling R, Karre K. Immunization against tumor and minor histocompatibility antigens by eluted cellular peptides loaded on antigen processing defective cells. Eur J Immunol 1993;23:2606-2613.
121. Wolpert E, Franksson L, Kärre K. Dominant and cryptic antigens in the MHC class I restricted T cell response across a complex minor histocompatibility barrier: analysis and mapping by elution of cellular peptides. Int Immunol 1995;7:919-928.
122. Nevala WK, Wettstein PJ. The preferential cytolytic T lymphocyte response to immunodominant minor histocompatiblity antigen peptides. Transplantation 1996;62:283-291.
123. Blazar BR, Roopenian DC, Taylor PA, Christianson GJ, Panokaltsis-Mortari A, Vallera DA. Lack of GVHD across classical single minor histocompatibility (miH) locus barriers in mice. Transplantation 1996;61:619-624.
124. Perreault C, Jutras J, Roy DC, Filep JG, Brochu S. Identification of an immunodominant mouse minor histocompatibility antigen (MiHA). T cell response to a single dominant MiHA causes graft-versus-host disease. J Clin Invest 1996;98:622-628.
125. Storb R, et al. Methotrexate and cyclosporine compared with cyclosporine alone for prophylaxis of acute graft-versus-host-disease after marrow transplantation for leukemia. N Engl J Med 1986;314:829-835.
126. Wettstein PJ. Immunodominance in the T cell response to multiple non-H-2 histocompatibility antigens. III. Single histocompatibility antigens dominate the male antigen. J Immunol 1986;137:2073-2079.
127. Von Boehmer H, Haas W. Distinct Ir genes for helper and killer cells in the cytotoxic response to H-Y antigen. J Exp Med 1979;150:1134-1142.
128. Davis AP, Roopenian DC. Complexity at the mouse minor histocompatibility locus H-4. Immunogenetics 1990;31:7-12.
129. Roopenian DC, Davis AP, Christianson GJ, Mobraaten LE. The functional basis of minor histocompatibility loci. J Immunol 1993;151:4595-4605.
130. Zuberi AR, Nguyen HQ, Auman HJ, Taylor BA, Roopenian DC. A genetic linkage map of mouse chromosome 2 extending from thrombospondin to paired box gene 1, including the H3 minor histocompatibility complex. Genomics 1996;33:75-84.
131. + T cells specifically recognize a shared melanoma-assoicated antigen encoded by the tyrosinase gene. Proc Natl Acad Sci USA 1994;91:9461-9465.
132. - strains. Proc Natl Acad Sci USA 1994;91: 11482-11486.
133. Chen W, Khilko S, Fecondo J, Margulies DH, McCluskey J. Determinant selection of major histocompatibility complex class I restricted antigenic peptides is explained by class I peptide affinity and is strongly influenced by nondominant anchor residues. J Exp Med 1994;180:1471-1483.
134. Wettstein PJ, Van Bleek GM, Nathenson SG. Differential binding of a minor histocompatibility antigen peptide to H-2 class I molecules correlates with immune responsiveness. J Immunol 1993;150:2753-2760.
135. Chen Y, et al. Naturally processed peptides longer than nine amino acid residues bind to the class I molecule HLA-A2.1 with high affinity and in different confirmations. J Immunol 1994;152:2874-2881.
136. Ruppert J, Sidney J, Cells E, Kubo R, Grey HM, Sette A. Prominant role of secondary anchor residue in peptide binding to HLA-A2.1 molecules. Cell 1993;74:929-937.
137. Cox AL, et al. Identification of a peptide recognized by five melanoma-specific human cytotoxic T cell lines. Science 1994;264:716-719.
138. Krenger A, Ferrara JLM. Dysregulation of cytokines graft-versus-host disease. J Hematother 1996;5:3-14.
139. Abhyankar S, Gilliland DG, Ferrara JLM. Interleukin 1 is a critical effector molecule during cytokine dysregulation in graft versus host disease to minor histocompatibility antigens. Transplantation 1993;56:1518-1523.
140. Piguet PF, Grau GE, Allet B, Vassalli P. Tumor necrosis factor cachetin is an effector of skin and gut in the acute phase of GVHD. J Exp Med 1987;166:1280-1289.
141. + T cell clones specific for non H-2 antigens. J Immunol 1990;145:2123-2131.
142. Hirokawa M, et al. Lymphokine acitivity production in graft-verus-host reactions across minor histocompatibility antigen barriers. Clin Exp Immunol 1989;66:434-439.
143. Dickinson AM, et al. Cytokine involvement in predicting test for graft-versus-host disease in allogeneic bone marrow transplant recipients. Bone Marrow Transplant 1994;13:65-70.
144. Van Lochern EG, Van der Keur M, Mommaas M, De Gast GC, Goulmy E. Expression of cytotoxic T cell defined minor histocompatibility antigens on human peripheral blood dendritic cells and skin derived Langerhans cells. Transpl Immunol 1996;4:151-157.
145. Macatonia SE, Taylor PM, Knight SC, Askonas BA. Primary stimulation by dendritic cells induces antiviral proliferative and cytotoxic T cell responses in vitro. J Exp Med 1989;169:1255-1264.
146. Melief CJM. Dendritic cells as specialized antigen-presenting cells. Res Immunol 1989;140:902-906.
147. Perrauh C, et al. Persistence of host Langerhans cells following allogeneic bone marrow transplantation: possible relationship with acute graft-versus-host disease. Br J Haematol 1984;60:253-260.
148. Schlegel PG, et al. Prevention of graft-versus-host disease by peptides binding to class II major histocompatibility complex molecules. Blood 1994;84:2802-2810.
149. Schlegel PG, Aharoni R, Vaysburd M, Tran N, McDevitt HO, Chao NJ. Inhibition of secondary MLR and prevention of murine graft-versus-host disease across minor histocompatibility barriers by peptides with high binding affinity for class II MHC molecules. FASEB J 1994;8:478(Abstract).
150. Sloan-Lancaster J, Allen PM. Altered peptide ligant-induced partial T cell activation: molecular mechanisms and role in T cell biology. Annu Rev Immunol 1996;14:1-27.
151. Klenermann P, Meier UC, Philips RE, McMichael AJ. The effects of natural altered peptide ligangs on the whole blood cytotoxic T lymphocyte response to human immunodeficiency virus. J Immunol 1995;25:1927-1931.
152. Snoke K, et al. The inhibition of different T cell lines specific for the same antigen with TCR antagonist peptides. J Immunol 1993;151:6815-6821.
153. Brochu S, Roy DC, Perreault C. Tolerance to host minor histocompatibility antigens after allogeneic bone marrow transplantation. J Immunol 1992;149:3135-3141.
154. Brochu S, Baron C, Bélanger R, Perreault C. Graft-host tolerance in bone marrow transplant chimeras. Absence of graft-versus host disease is associated with unresponsiveness to minor histocompatibility antigens expressed by all tissues. Blood 1994;84:3221-3228.
155. Irschick EU, et al. Studies on the mechanism of tolerance for graft-versus-host disease in allogeneic bone marrow recipients at the level of cytotoxic T cell precursor frequencies. Blood 1992;79:1622-1628.
156. De Bueger M, Bakker A, Goulmy E. Acquired tolerance for minor histocompatibility antigens after HLA identical bone marrow transplantation, Int Immunol 1992;4:53-57.
157. Davies JD, Leong LYW, Mellor A, Cobbold SP, Waldmann H. T cell suppression in transplantation tolerance through linked recognition. J Immunol 1996;156:3602-3607.
158. Giralt SA, Champlin RE. Leukemia relapse after allogeneic bone marrow transplantation. Blood 1994;84:3603-3612.
159. Kolb HJ, et al. Donor leukocyte transfusions for treatment of recurrent chronic mycologenous leukemia in marrow transplant patients. Blood 1990;76:2462-2465.
160. Hertenstein B, et al. Interferon α and donor buffycoat transfusions for treatment of relapsed chronic myeloid leukemia after allogeneic bone marrow transplantation. Transplantation 1993;56:1114-1118.
161. Slavin S, Naparstek E, Nagler A, Ackerstein A, Kapelushnik J, Or R. Allogeneic cell therapy for relapsed leukemia after bone marrow transplantation with donor peripheral blood lymphocytes. Exp Hematol 1995;23:1553-1562.
162. Antin JH. Graft-versus-leukemia. No longer an epiphenomenon. Blood 1993;82:2272-2277.
163. Kolb HJ, et al. Graft-versus-leukemia effect of donor lymphocyte transfusions in marrow grafted patients. Blood 1995;86:2041-2050.
164. Rooney CM, et al. Use of gene-modified virus-specific T lymphocytes to control of Epstein-Barr virus related lymphoproliferation. Lancet 1995;345:9-13.
165. Riddell SR, Greenberg PD. Principles for adoptive T cell therapy of human viral diseases. Annu Rev Immunol 1995;13:545-586.
166. Van der Harst D, et al. Recognition of minor histocompatibility antigens on lymphocytic and myeloid leukemic cells by cytotoxic T cell clones. Blood 1994;83:1060-1066.
167. Falkenburg JHF, et al. Growth inhibition of clonogenic leukemic precursor cells by histocompatibility antigen-specific cytotoxic T lymphocytes. J Exp Med 1991;174:27-33.